Home Healthcare IT Advanced Therapy Medicinal Products (ATMP) Market Size by 2032

Advanced Therapy Medicinal Products (ATMP) Market Size & Outlook, 2024-2032

Advanced Therapy Medicinal Products (ATMP) Market Size, Share & Trends Analysis Report By Therapy Type (Cell Therapy, Gene Therapy, CAR-T Therapy, Tissue Engineered Products), By Manufacturer (Biopharmaceutical Companies, Contract Development and Manufacturing Organizations (CDMOs), Others) and By Region (North America, Europe, APAC, Middle East and Africa, LATAM) Forecasts, 2024-2032

Report Code: SRHI54723DR
Last Updated: Oct, 2024
Pages: 110
Author: Debashree Bora
Format: PDF, Excel

Table Of Content

  1. Executive Summary
    1. Research Objectives
    2. Limitations & Assumptions
    3. Market Scope & Segmentation
    4. Currency & Pricing Considered
    1. Emerging Regions / Countries
    2. Emerging Companies
    3. Emerging Applications / End Use
    1. Drivers
    2. Market Warning Factors
    3. Latest Macro Economic Indicators
    4. Geopolitical Impact
    5. Technology Factors
    1. Porters Five Forces Analysis
    2. Value Chain Analysis
    1. North America
    2. Europe
    3. APAC
    4. Middle East and Africa
    5. LATAM
  2. ESG Trends
    1. Global Advanced Therapy Medicinal Products (ATMP) Market Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell Therapy
        1. By Value
      3. Gene Therapy
        1. By Value
      4. CAR-T Therapy
        1. By Value
      5. Tissue Engineered Products
        1. By Value
    3. By Manufacturer
      1. Introduction
        1. Manufacturer By Value
      2. Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations (CDMOs)
        1. By Value
      4. Others
        1. By Value
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell Therapy
        1. By Value
      3. Gene Therapy
        1. By Value
      4. CAR-T Therapy
        1. By Value
      5. Tissue Engineered Products
        1. By Value
    3. By Manufacturer
      1. Introduction
        1. Manufacturer By Value
      2. Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations (CDMOs)
        1. By Value
      4. Others
        1. By Value
    4. U.S.
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell Therapy
          1. By Value
        3. Gene Therapy
          1. By Value
        4. CAR-T Therapy
          1. By Value
        5. Tissue Engineered Products
          1. By Value
      2. By Manufacturer
        1. Introduction
          1. Manufacturer By Value
        2. Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations (CDMOs)
          1. By Value
        4. Others
          1. By Value
    5. Canada
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell Therapy
        1. By Value
      3. Gene Therapy
        1. By Value
      4. CAR-T Therapy
        1. By Value
      5. Tissue Engineered Products
        1. By Value
    3. By Manufacturer
      1. Introduction
        1. Manufacturer By Value
      2. Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations (CDMOs)
        1. By Value
      4. Others
        1. By Value
    4. U.K.
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell Therapy
          1. By Value
        3. Gene Therapy
          1. By Value
        4. CAR-T Therapy
          1. By Value
        5. Tissue Engineered Products
          1. By Value
      2. By Manufacturer
        1. Introduction
          1. Manufacturer By Value
        2. Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations (CDMOs)
          1. By Value
        4. Others
          1. By Value
    5. Germany
    6. France
    7. Spain
    8. Italy
    9. Russia
    10. Nordic
    11. Benelux
    12. Rest of Europe
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell Therapy
        1. By Value
      3. Gene Therapy
        1. By Value
      4. CAR-T Therapy
        1. By Value
      5. Tissue Engineered Products
        1. By Value
    3. By Manufacturer
      1. Introduction
        1. Manufacturer By Value
      2. Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations (CDMOs)
        1. By Value
      4. Others
        1. By Value
    4. China
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell Therapy
          1. By Value
        3. Gene Therapy
          1. By Value
        4. CAR-T Therapy
          1. By Value
        5. Tissue Engineered Products
          1. By Value
      2. By Manufacturer
        1. Introduction
          1. Manufacturer By Value
        2. Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations (CDMOs)
          1. By Value
        4. Others
          1. By Value
    5. Korea
    6. Japan
    7. India
    8. Australia
    9. Singapore
    10. Taiwan
    11. South East Asia
    12. Rest of Asia-Pacific
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell Therapy
        1. By Value
      3. Gene Therapy
        1. By Value
      4. CAR-T Therapy
        1. By Value
      5. Tissue Engineered Products
        1. By Value
    3. By Manufacturer
      1. Introduction
        1. Manufacturer By Value
      2. Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations (CDMOs)
        1. By Value
      4. Others
        1. By Value
    4. UAE
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell Therapy
          1. By Value
        3. Gene Therapy
          1. By Value
        4. CAR-T Therapy
          1. By Value
        5. Tissue Engineered Products
          1. By Value
      2. By Manufacturer
        1. Introduction
          1. Manufacturer By Value
        2. Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations (CDMOs)
          1. By Value
        4. Others
          1. By Value
    5. Turkey
    6. Saudi Arabia
    7. South Africa
    8. Egypt
    9. Nigeria
    10. Rest of MEA
    1. Introduction
    2. By Therapy Type
      1. Introduction
        1. Therapy Type By Value
      2. Cell Therapy
        1. By Value
      3. Gene Therapy
        1. By Value
      4. CAR-T Therapy
        1. By Value
      5. Tissue Engineered Products
        1. By Value
    3. By Manufacturer
      1. Introduction
        1. Manufacturer By Value
      2. Biopharmaceutical Companies
        1. By Value
      3. Contract Development and Manufacturing Organizations (CDMOs)
        1. By Value
      4. Others
        1. By Value
    4. Brazil
      1. By Therapy Type
        1. Introduction
          1. Therapy Type By Value
        2. Cell Therapy
          1. By Value
        3. Gene Therapy
          1. By Value
        4. CAR-T Therapy
          1. By Value
        5. Tissue Engineered Products
          1. By Value
      2. By Manufacturer
        1. Introduction
          1. Manufacturer By Value
        2. Biopharmaceutical Companies
          1. By Value
        3. Contract Development and Manufacturing Organizations (CDMOs)
          1. By Value
        4. Others
          1. By Value
    5. Mexico
    6. Argentina
    7. Chile
    8. Colombia
    9. Rest of LATAM
    1. Advanced Therapy Medicinal Products (ATMP) Market Share By Players
    2. M&A Agreements & Collaboration Analysis
    1. Spark Therapeutics, Inc.
      1. Overview
      2. Business Information
      3. Revenue
      4. ASP
      5. SWOT Analysis
      6. Recent Developments
    2. Organogenesis Inc.
    3. Bluebird Bio, Inc.
    4. Novartis AG
    5. Bristol-Myers Squibb
    6. Gilead Lifesciences, Inc.
    7. Kolon TissueGene, Inc.
    8. MEDIPOST
    9. JCR Pharmaceuticals Co., Ltd.
    10. Vericel Corporation
    11. UniQure N.V.
    12. Celgene Corporation
    13. Corning Incorporated
    14. Cytiva
    15. Astellas Pharma Inc.
    16. PHARMICELL Co., Ltd
    17. Orchard Therapeutics
    1. Research Data
      1. Secondary Data
        1. Major secondary sources
        2. Key data from secondary sources
      2. Primary Data
        1. Key data from primary sources
        2. Breakdown of primaries
      3. Secondary And Primary Research
        1. Key industry insights
    2. Market Size Estimation
      1. Bottom-Up Approach
      2. Top-Down Approach
      3. Market Projection
    3. Research Assumptions
      1. Assumptions
    4. Limitations
    5. Risk Assessment
    1. Discussion Guide
    2. Customization Options
    3. Related Reports
  3. Disclaimer
Get This Report

Download Free Sample

Our Clients:

LG Electronics
AMCAD Engineering
KOBE STEEL LTD.
Hindustan National Glass & Industries Limited
Voith Group
International Paper
Hansol Paper
Whirlpool Corporation
Sony
Samsung Electronics
Qualcomm
Google
Fiserv
Veto-Pharma
Nippon Becton Dickinson
Merck
Argon Medical Devices
Abbott
Ajinomoto
Denon
Doosan
Meiji Seika Kaisha Ltd
LG Chemicals
LCY chemical group
Bayer
Airrane
BASF
Toyota Industries
Nissan Motors
Neenah
Mitsubishi
Hyundai Motor Company

We are featured on:

WhatsApp
Chat with us on WhatsApp
Address:
Office 515 A, Amanora Chambers,
Amanora Park Town, Hadapsar,
Pune 411028, Maharashtra, India.
Contact Us:
+1 646 905 0080 (U.S.)
+91 8087085354 (India)
+44 203 695 0070 (U.K.)

sales@straitsresearch.com

Quick Links
Help
Verified. Protected. Secure.
DMCA.com Protection Status
Secure Payments:
Follow Us:
www.straitsresearch.com © Copyright . All rights Reserved.